TransCode Therapeutics announced that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer, CMO. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
- Transcode Therapeutics, Akribion report progress on CRISPR-derived tech
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
- Transcode Therapeutics reports publication of U.S. patent application
